Last reviewed · How we verify
SGN-15, Docetaxel
At a glance
| Generic name | SGN-15, Docetaxel |
|---|---|
| Sponsor | Seagen Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma (PHASE2)
- Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer (PHASE2)
- Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer (PHASE2)
- FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SGN-15, Docetaxel CI brief — competitive landscape report
- SGN-15, Docetaxel updates RSS · CI watch RSS
- Seagen Inc. portfolio CI